Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades

Table 2

Percentage survival at two and five years by prognostic factors.

	2yOS		5yOS
	%	95% CI	%	95% CI
Entire cohort	8.0	(7.9–8.2)	2.1	(2.0–2.1)
Age
<67	9.5	(9.3–9.6)	2.7	(2.6–2.7)
≧67	6.6	(6.5–6.7)	1.5	(1.5–1.6)
Sex
Male	6.3	(6.1–6.4)	1.6	(1.5–1.7)
Female	10.5	(10.3–10.7)	2.8	(2.7–2.9)
Race
White	7.5	(7.4–7.7)	2	(1.9–2.0)
Black	7.2	(6.9–7.5)	1.8	(1.7–2.0)
American Indian/Alaska native	8.6	(7.0–10.4)	1.5	(0.8–2.6)
Asian/Pacific Islander	15.1	(14.5–15.6)	4.1	(3.7–4.4)
Unk/oth	23.1	(17.6–29.1)	15.1	(9.8–21.5)
Marital status
Single	7.0	(6.9–7.2)	1.8	(1.7–1.9)
Married	8.7	(8.6–8.9)	2.3	(2.2–2.4)
Histology
Adenocarcinoma	10.8	(10.6–11)	2.7	(2.6–2.8)
Lung carcinoma NOS	5.1	(5.0–5.3)	1.3	(1.3–1.4)
Squamous cell carcinoma	6.2	(6.0–6.4)	1.8	(1.7–1.9)
Small-cell carcinoma	4.4	(4.3–4.6)	1.3	(1.2–1.4)
Grade
Well differentiated	18.6	(17.6–19.7)	6.3	(5.6–7.0)
Moderately differentiated	13.2	(12.8–13.7)	3.8	(3.5–4.1)
Poorly differentiated	7.1	(6.9–7.3)	2.0	(1.9–2.1)
Undifferentiated	4.5	(4.1–4.8)	1.3	(1.1–1.5)
Year of diagnosis
1973–79	3.1	(2.9–3.4)	0.7	(0.6–0.9)
1980–89	3.5	(3.3–3.7)	0.9	(0.8–1.0)
1990–99	4.5	(4.3–4.7)	1.1	(1.0–1.2)
2000–09	8.4	(8.3–8.6)	2.1	(2.0–2.2)
2010–15	12.6	(12.3–12.9)	3.7	(3.5–3.9)
Treatment
None	4.5	(4.3–4.6)	1.6	(1.5–1.7)
Chemotherapy only	14.9	(14.6–15.2)	3.3	(3.1–3.5)
Radiotherapy (RT) only	4.0	(3.9–4.2)	1.0	(1.0–1.1)
Chemotherapy + RT	11.7	(11.5–12)	2.9	(2.8–3.1)
Income
<median^a	7.2	(7.0–7.4)	1.9	(1.8–2.0)
≧median^a	8.5	(8.4–8.7)	2.2	(2.1–2.3)

2yOS: two-year overall survival. 5yOS: five-year overall survival. CI: confidence interval. NOS: non-other specified. Ca: carcinoma. ^aAnnual county median in 2010 of $52,595.